Literature DB >> 12925253

Gene therapy: a primer for neurosurgeons.

E Antonio Chiocca1.   

Abstract

Gene therapy involves the transfer of genes into cells with therapeutic intent. Although several methods can accomplish this, vectors based on viruses still provide the most efficient approach. For neurosurgical purposes, preclinical and clinical applications in the areas of glioma therapy, spinal neurosurgery, and neuroprotection for treatment of Parkinson's disease and cerebral ischemia are reviewed. In general, therapies applied in the neurosurgical realm have proven relatively safe, despite occasional, well-publicized cases of morbidity and death in non-neurosurgical trials. However, continued clinical and preclinical research in this area is critical, to fully elucidate potential toxicities and to generate truly effective treatments that can be applied in neurological diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12925253     DOI: 10.1227/01.neu.0000073532.05714.2b

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  5 in total

1.  Intrathecal gene therapy for treatment of leptomeningeal carcinomatosis.

Authors:  John D Heiss; Sara Taha; Edward H Oldfield; Zvi Ram
Journal:  J Neurooncol       Date:  2010-11-26       Impact factor: 4.130

Review 2.  Neurosurgical delivery of chemotherapeutics, targeted toxins, genetic and viral therapies in neuro-oncology.

Authors:  E Antonio Chiocca; William C Broaddus; George T Gillies; Therese Visted; Martine L M Lamfers
Journal:  J Neurooncol       Date:  2004 Aug-Sep       Impact factor: 4.130

Review 3.  Gene therapy as an adjuvant treatment for malignant gliomas: from bench to bedside.

Authors:  Isabelle M Germano; Emanuela Binello
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

4.  GNOSIS: guidelines for neuro-oncology: standards for investigational studies--reporting of surgically based therapeutic clinical trials.

Authors:  Susan Chang; Michael Vogelbaum; Frederick F Lang; Stephen Haines; Sandeep Kunwar; E Antonio Chiocca; Alessandro Olivi; Alfredo Quinones-Hinojosa; Andrew Parsa; Ronald Warnick
Journal:  J Neurooncol       Date:  2006-12-05       Impact factor: 4.506

5.  Embryonic stem cell (ESC)-mediated transgene delivery induces growth suppression, apoptosis and radiosensitization, and overcomes temozolomide resistance in malignant gliomas.

Authors:  I M Germano; L Emdad; Z A Qadeer; E Binello; M Uzzaman
Journal:  Cancer Gene Ther       Date:  2010-06-04       Impact factor: 5.987

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.